News | Travere Therapeutics - Part 2

<img width="395" height="386" alt="Travere Circle Logo" data-srcset="https://vru6bs9lpn-flywheel.netdna-ssl.com/wp-content/uploads/Retrophin-Solo-full-color.png 395w, https://vru6bs9lpn-flywheel.netdna-ssl.com/wp-content/uploads/Retrophin-Solo-full-color-350x342.png 350w, https://vru6bs9lpn-flywheel.netdna-ssl.com/wp-content/uploads/Retrophin-Solo-full-color-36x36.png 36w" data-src="https://vru6bs9lpn-flywheel.netdna-ssl.com/wp-content/uploads/Retrophin-Solo-full-color.png" data-sizes="(max-width: 395px) 100vw, 395px" class="wp-image-4894 avia-img-lazy-loading-not-4894 attachment-portfolio size-portfolio wp-post-image lazyload" src="data:image/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw==" /><noscript><img width="395" height="386" alt="Travere Circle Logo" data-srcset="https://vru6bs9lpn-flywheel.netdna-ssl.com/wp-content/uploads/Retrophin-Solo-full-color.png 395w, https://vru6bs9lpn-flywheel.netdna-ssl.com/wp-content/uploads/Retrophin-Solo-full-color-350x342.png 350w, https://vru6bs9lpn-flywheel.netdna-ssl.com/wp-content/uploads/Retrophin-Solo-full-color-36x36.png 36w" data-src="https://vru6bs9lpn-flywheel.netdna-ssl.com/wp-content/uploads/Retrophin-Solo-full-color.png" data-sizes="(max-width: 395px) 100vw, 395px" class="wp-image-4894 avia-img-lazy-loading-not-4894 attachment-portfolio size-portfolio wp-post-image lazyload" src="data:image/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw==" /><noscript><img width="395" height="386" src="https://vru6bs9lpn-flywheel.netdna-ssl.com/wp-content/uploads/Retrophin-Solo-full-color.png" class="wp-image-4894 avia-img-lazy-loading-not-4894 attachment-portfolio size-portfolio wp-post-image" alt="Travere Circle Logo" srcset="https://vru6bs9lpn-flywheel.netdna-ssl.com/wp-content/uploads/Retrophin-Solo-full-color.png 395w, https://vru6bs9lpn-flywheel.netdna-ssl.com/wp-content/uploads/Retrophin-Solo-full-color-350x342.png 350w, https://vru6bs9lpn-flywheel.netdna-ssl.com/wp-content/uploads/Retrophin-Solo-full-color-36x36.png 36w" sizes="(max-width: 395px) 100vw, 395px" />

Retrophin Announces Agreement to Acquire Orphan Technologies

SAN DIEGO, Oct. 22, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that it has entered into a definitive agreement to acquire Orphan Technologies Limited, a privately held, clinical-stage biopharmaceutical company focused on the development of product candidate OT-58 for the treatment of classical homocystinuria (HCU). Read the press release >

<img width="395" height="386" alt="Travere Circle Logo" data-srcset="https://vru6bs9lpn-flywheel.netdna-ssl.com/wp-content/uploads/Retrophin-Solo-full-color.png 395w, https://vru6bs9lpn-flywheel.netdna-ssl.com/wp-content/uploads/Retrophin-Solo-full-color-350x342.png 350w, https://vru6bs9lpn-flywheel.netdna-ssl.com/wp-content/uploads/Retrophin-Solo-full-color-36x36.png 36w" data-src="https://vru6bs9lpn-flywheel.netdna-ssl.com/wp-content/uploads/Retrophin-Solo-full-color.png" data-sizes="(max-width: 395px) 100vw, 395px" class="wp-image-4894 avia-img-lazy-loading-not-4894 attachment-portfolio size-portfolio wp-post-image lazyload" src="data:image/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw==" /><noscript><img width="395" height="386" alt="Travere Circle Logo" data-srcset="https://vru6bs9lpn-flywheel.netdna-ssl.com/wp-content/uploads/Retrophin-Solo-full-color.png 395w, https://vru6bs9lpn-flywheel.netdna-ssl.com/wp-content/uploads/Retrophin-Solo-full-color-350x342.png 350w, https://vru6bs9lpn-flywheel.netdna-ssl.com/wp-content/uploads/Retrophin-Solo-full-color-36x36.png 36w" data-src="https://vru6bs9lpn-flywheel.netdna-ssl.com/wp-content/uploads/Retrophin-Solo-full-color.png" data-sizes="(max-width: 395px) 100vw, 395px" class="wp-image-4894 avia-img-lazy-loading-not-4894 attachment-portfolio size-portfolio wp-post-image lazyload" src="data:image/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw==" /><noscript><img width="395" height="386" src="https://vru6bs9lpn-flywheel.netdna-ssl.com/wp-content/uploads/Retrophin-Solo-full-color.png" class="wp-image-4894 avia-img-lazy-loading-not-4894 attachment-portfolio size-portfolio wp-post-image" alt="Travere Circle Logo" srcset="https://vru6bs9lpn-flywheel.netdna-ssl.com/wp-content/uploads/Retrophin-Solo-full-color.png 395w, https://vru6bs9lpn-flywheel.netdna-ssl.com/wp-content/uploads/Retrophin-Solo-full-color-350x342.png 350w, https://vru6bs9lpn-flywheel.netdna-ssl.com/wp-content/uploads/Retrophin-Solo-full-color-36x36.png 36w" sizes="(max-width: 395px) 100vw, 395px" />

Retrophin Announces Presentation of Abstracts at ASN Kidney Week 2020 Reimagined

SAN DIEGO, Oct. 09, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that it will present new data from a post-hoc analysis examining the proportion of patients with focal segmental glomerulosclerosis (FSGS) that achieved complete remission of proteinuria in the Phase 2 DUET Study, at the American Society of Nephrology (ASN) Kidney Week 2020 Reimagined. Read the press release >

<img width="395" height="386" alt="Travere Circle Logo" data-srcset="https://vru6bs9lpn-flywheel.netdna-ssl.com/wp-content/uploads/Retrophin-Solo-full-color.png 395w, https://vru6bs9lpn-flywheel.netdna-ssl.com/wp-content/uploads/Retrophin-Solo-full-color-350x342.png 350w, https://vru6bs9lpn-flywheel.netdna-ssl.com/wp-content/uploads/Retrophin-Solo-full-color-36x36.png 36w" data-src="https://vru6bs9lpn-flywheel.netdna-ssl.com/wp-content/uploads/Retrophin-Solo-full-color.png" data-sizes="(max-width: 395px) 100vw, 395px" class="wp-image-4894 avia-img-lazy-loading-not-4894 attachment-portfolio size-portfolio wp-post-image lazyload" src="data:image/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw==" /><noscript><img width="395" height="386" alt="Travere Circle Logo" data-srcset="https://vru6bs9lpn-flywheel.netdna-ssl.com/wp-content/uploads/Retrophin-Solo-full-color.png 395w, https://vru6bs9lpn-flywheel.netdna-ssl.com/wp-content/uploads/Retrophin-Solo-full-color-350x342.png 350w, https://vru6bs9lpn-flywheel.netdna-ssl.com/wp-content/uploads/Retrophin-Solo-full-color-36x36.png 36w" data-src="https://vru6bs9lpn-flywheel.netdna-ssl.com/wp-content/uploads/Retrophin-Solo-full-color.png" data-sizes="(max-width: 395px) 100vw, 395px" class="wp-image-4894 avia-img-lazy-loading-not-4894 attachment-portfolio size-portfolio wp-post-image lazyload" src="data:image/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw==" /><noscript><img width="395" height="386" src="https://vru6bs9lpn-flywheel.netdna-ssl.com/wp-content/uploads/Retrophin-Solo-full-color.png" class="wp-image-4894 avia-img-lazy-loading-not-4894 attachment-portfolio size-portfolio wp-post-image" alt="Travere Circle Logo" srcset="https://vru6bs9lpn-flywheel.netdna-ssl.com/wp-content/uploads/Retrophin-Solo-full-color.png 395w, https://vru6bs9lpn-flywheel.netdna-ssl.com/wp-content/uploads/Retrophin-Solo-full-color-350x342.png 350w, https://vru6bs9lpn-flywheel.netdna-ssl.com/wp-content/uploads/Retrophin-Solo-full-color-36x36.png 36w" sizes="(max-width: 395px) 100vw, 395px" />

Retrophin Announces Enrollment of First 280 Patients in Pivotal Phase 3 PROTECT Study of Sparsentan in IgA Nephropathy

SAN DIEGO, Sept. 21, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that the first 280 patients have been enrolled in the pivotal Phase 3 PROTECT Study evaluating the safety and efficacy of sparsentan in IgA nephropathy (IgAN). Read the press release >

Eric Dube, Ph.D., Speaks at Black Women’s Health Imperative Event

August 12, 2020 - the Black Women’s Health Imperative hosted a national webinar with its partner, the National Coalition of 100 Black Women, Inc. entitled “Our Health, Our Community: Mobilizing for the Survival of Black Women,” in partnership with EBONY.

Retrophin President and Chief Executive Officer Eric Dube Named to the 2020 PharmaVOICE 100

SAN DIEGO (August 3, 2020) – Retrophin, Inc. (NASDAQ: RTRX) today announced that Eric Dube, Ph.D., president and chief executive officer, has been named by PharmaVOICE magazine to the 2020 PharmaVOICE 100 – an award that recognizes the 100 Most Inspiring People in the life sciences industry. Read the press release >

<img width="395" height="386" alt="Travere Circle Logo" data-srcset="https://vru6bs9lpn-flywheel.netdna-ssl.com/wp-content/uploads/Retrophin-Solo-full-color.png 395w, https://vru6bs9lpn-flywheel.netdna-ssl.com/wp-content/uploads/Retrophin-Solo-full-color-350x342.png 350w, https://vru6bs9lpn-flywheel.netdna-ssl.com/wp-content/uploads/Retrophin-Solo-full-color-36x36.png 36w" data-src="https://vru6bs9lpn-flywheel.netdna-ssl.com/wp-content/uploads/Retrophin-Solo-full-color.png" data-sizes="(max-width: 395px) 100vw, 395px" class="wp-image-4894 avia-img-lazy-loading-not-4894 attachment-portfolio size-portfolio wp-post-image lazyload" src="data:image/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw==" /><noscript><img width="395" height="386" alt="Travere Circle Logo" data-srcset="https://vru6bs9lpn-flywheel.netdna-ssl.com/wp-content/uploads/Retrophin-Solo-full-color.png 395w, https://vru6bs9lpn-flywheel.netdna-ssl.com/wp-content/uploads/Retrophin-Solo-full-color-350x342.png 350w, https://vru6bs9lpn-flywheel.netdna-ssl.com/wp-content/uploads/Retrophin-Solo-full-color-36x36.png 36w" data-src="https://vru6bs9lpn-flywheel.netdna-ssl.com/wp-content/uploads/Retrophin-Solo-full-color.png" data-sizes="(max-width: 395px) 100vw, 395px" class="wp-image-4894 avia-img-lazy-loading-not-4894 attachment-portfolio size-portfolio wp-post-image lazyload" src="data:image/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw==" /><noscript><img width="395" height="386" src="https://vru6bs9lpn-flywheel.netdna-ssl.com/wp-content/uploads/Retrophin-Solo-full-color.png" class="wp-image-4894 avia-img-lazy-loading-not-4894 attachment-portfolio size-portfolio wp-post-image" alt="Travere Circle Logo" srcset="https://vru6bs9lpn-flywheel.netdna-ssl.com/wp-content/uploads/Retrophin-Solo-full-color.png 395w, https://vru6bs9lpn-flywheel.netdna-ssl.com/wp-content/uploads/Retrophin-Solo-full-color-350x342.png 350w, https://vru6bs9lpn-flywheel.netdna-ssl.com/wp-content/uploads/Retrophin-Solo-full-color-36x36.png 36w" sizes="(max-width: 395px) 100vw, 395px" />

Retrophin Reports Second Quarter 2020 Financial Results

SAN DIEGO, July 30, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today reported its second quarter 2020 financial results and provided a corporate update. Read the press release >

Marshall Summar, M.D., CNRDI

Connecting More People to Optimal Rare Disease Care

News, Stories & Insights

An update on our partnership with Children's National Rare Disease Institute.

Eric Dube, Ph.D., Interviewed by Rare Revolution

July 1, 2020 -- Our CEO and president Eric Dube, Ph.D., recently spoke with Rare Revolution Magazine about motivation, inspiration, challenges and hope.

© 2021 Travere Therapeutics, Inc. All rights reserved. For US audiences. Chenodal®, Cholbam® and Total Care HUB® are registered trademarks of Travere Therapeutics, Inc. Thiola® and Thiola EC® are registered trademarks of Mission Pharmacal Company.

Terms and Conditions | Privacy Policies